Contact
searchSearch
HMP Global
Login
Quiz

Novel Anti-CSF1 Receptor Antibody for Tenosynovial Giant Cell Tumor

11/20/2025

Related Content

FDA Alerts
FDA Accepts New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor
02/06/2026
Stephanie Holland
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase...
02/06/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Clinical Experience With Pediatric Tenosynovial Giant Cell Tumor: A Single-Center Observational Study
12/18/2025
Emily Estrada
A single-center observational explored real-world clinical presentation, imaging findings, treatment strategies, and long-term outcomes of pediatric patients with tenosynovial giant cell tumor.
A single-center observational explored real-world clinical presentation, imaging findings, treatment strategies, and long-term outcomes of pediatric patients with tenosynovial giant cell tumor.
A single-center observational...
12/18/2025
Oncology
Quiz
Molecular Drivers of Pigmented Villonodular Synovitis
12/18/2025
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular features were found to be most strongly associated with disease progression in pigmented villonodular synovitis?
Which of the following molecular...
12/18/2025
Oncology

Recent News

Conference Coverage
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical Takeaways:  Design/Population: This retrospective study evaluated plasma ctDNA in 42 patients with muscle-invasive bladder cancer treated with trimodality therapy. Patients were stratified by post-treatment ctDNA...
Key Clinical...
02/09/2026
Oncology
Conference Coverage
Selective Use of Stereotactic Ablative Radiotherapy Enables Durable Disease Control in Oligoprogressive Metastatic Renal Cell Carcinoma
02/06/2026
Stephanie Holland
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative...
02/06/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Pimicotinib in Tenosynovial Giant Cell Tumor
02/06/2026
Stephanie Holland
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase 3 MANEUVER trial, the FDA accepted the New Drug Application for pimicotinib for the treatment of patients with tenosynovial giant cell tumor.
Based on results from the phase...
02/06/2026
Oncology
News
LDH and α-HBDH as Prognostic Biomarkers in Extensive-Stage Small Cell Lung Cancer
02/06/2026
Emily Estrada
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early on-treatment serum levels of LDH and α-HBDH following first-line chemoimmunotherapy were independently associated with survival outcomes in extensive-stage small cell lung cancer.
Elevated baseline and early...
02/06/2026
Oncology
News
Zanzalintinib Plus Atezolizumab Significantly Improves OS in Relapsed or Refractory Metastatic Colorectal Cancer
02/06/2026
Stephanie Holland
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab significantly improves overall survival compared with regorafenib in relapsed or refractory metastatic colorectal cancer without MSI-H or dMMR tumors.
Results from the STELLAR-303...
02/06/2026
Oncology
News
¹⁸F-DOPA-PET Detects Early Treatment Response in IDH-Mutant Glioma
02/06/2026
Stephanie Holland
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world imaging analysis suggest that ¹⁸F-DOPA-PET and advanced MRI sequences may provide earlier indicators of treatment response than conventional MRI in patients with IDH-mutant glioma receiving IDH inhibitors.
Results from a real-world...
02/06/2026
Radiopharmaceutical Education Institute
News
Multi-Omics Model Accurately Predicts Radiotherapy Response in SCLC Brain Metastases
02/06/2026
Emily Estrada
Results from a retrospective analysis indicate that a multi-omics model integrating clinical, radiomic, and dosiomic features accurately predicts response to whole-brain radiotherapy in patients with small cell lung cancer brain metastases.
Results from a retrospective analysis indicate that a multi-omics model integrating clinical, radiomic, and dosiomic features accurately predicts response to whole-brain radiotherapy in patients with small cell lung cancer brain metastases.
Results from a retrospective...
02/06/2026
Oncology
News
Tinengotinib Demonstrates Strong Antitumor Activity in FGFR-Altered Cholangiocarcinoma
02/04/2026
Stephanie Holland
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial show that tinengotinib demonstrates strong antitumor activity in patients with advanced cholangiocarcinoma who developed resistance to prior FGFR inhibitor therapy.
Results from a phase 2 trial...
02/04/2026
Oncology
News
Fractionated Varnimcabtagene Autoleucel Achieves High MRD-Negative Response in Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
02/04/2026
Stephanie Holland
Results from the phase 2 CART19-BE-02 trial demonstrate that varnimcabtagene autoleucel produces high rates of complete remission with undetectable MRD in relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Results from the phase 2 CART19-BE-02 trial demonstrate that varnimcabtagene autoleucel produces high rates of complete remission with undetectable MRD in relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Results from the phase 2...
02/04/2026
Oncology
News
Identification of a High-Risk Subgroup With Poor Disease-Free Survival After Postoperative Radiotherapy for Cutaneous Squamous Cell Carcinoma
02/04/2026
Stephanie Holland
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from the phase 3 TROG 05.01 trial identified that patients with cutaneous squamous cell carcinoma of the head and neck who display higher risk features experience significantly worse DFS following postoperative...
Secondary analysis results from...
02/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use